ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, increased serum levels of TGF-ß and TNF-α at diagnosis were associated with low treatment response in CML that might have an important role as a clinical predictive biomarker.52 Codavarthyet al. demonstrated that expression of CD44 on BCR-ABL + LSC and E-selectin on bone marrow endothelium participates greatly in engraftment of LSC in bone marrow niche which protects the LSC from imatinib treatment.